1. Фтизиатрия. Национальное руководство/под ред. М.И. Перельмана. - М. ГЭОТАР-Медна, 2007. - 512 с.

2. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; approved standard. NCCLS document M-24A. Clinical and Laboratory Standards Institute, Wayne, PA, Vol. 26, N 23, 2007.

3. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol. 2002; 10: 45 - 52 10.1016/S0966-842X(01)02277-6.

4. Munro SA et al. Patient adherence to tuberculosis treatment: a systematic review of the Beijing strain family in Russia. Journal of the American Medical Association, 2005. 293: 2726 - 2731.

5. Vyazovaya A., Mokrousov I., Zhuravlev V., Solovieva N., Otten T., Vishnevsky B., Narvskaya O. Dominance of the Beijing genotype among XDR Mycobacterium tuberculosis strains in Russia/International Journal of Mycobacteriology, v. 4, (2015), p. 84 - 85.

6. World Health Organization. Tuberculosis handbook. Geneva: WHO, 1998.

7. WHO/IUATLD Antituberculosis drug resistance in the world. Report No 3. The WHO/IUATLD global project on antituberculosis drug resistance surveillance. Geneva: WHO, 2004.

8. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, World Health Organization, 2014 (http://www.who.int/tb/post2015_TBstrategy.pdf?ua=1, accessed 5 March 2015).

9. NIAID Tuberculosis Working Group. NIAID research agenda. Multidrug-resistant and extensively drug-resistant tuberculosis. 2007. URL: http://www3.niaid.nih.gov/topics/tuberculosis/Research/PDF/MDRXDRTBresearchAgenda06-06-07.pdf.

10. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. - 5th ed. Geneva: WHO, 2015.

11. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; No 81 (45): 430 - 432.

12. Sotgiu G., Ferrara G., Matteelli A. et al. Epidemiology and clinical management of XDR-TB: A systematic review by TBNET. Eur Respir J 2009; No 33 (4): 871 - 881.

13. World Health Organization. Global tuberculosis control. 2012: report. Geneve: WHO, 2012.

14. ЦНИИОИЗ/Центр мониторинга по туберкулеза/Аналитические обзоры/Ситуация по туберкулезу в 2017 года http://mednet.ru/images/stories/files/CMT/2017tb.pdf.

15. Sreeramareddy CT, Qin ZZ, Satyanarayana S, Subbaraman R, Pai M. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. Int J Tuberc Lung Dis. 2014; 18(3): 255 - 66.

16. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008; 8: 15.

17. Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, Rade K, Swaminathan S, Mayer KH. The Tuberculosis Cascade of Care in India"s Public Sector: A Systematic Review and Meta-analysis. PloS Med. 2016 Oct 25; 13(10): e1002149. doi: 10.1371/journal.pmed.1002149.

18. Rusen ID et al. Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome. International Journal of Tuberculosis and Lung Disease, 2007, 11: 120 - 121.

19. Kunkel A, Abel Zur Wiesch P, Nathavitharana RR, Marx FM, Jenkins HE, Cohen T. Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2016 Jun 13; 16: 282. doi: 10.1186/s12879-016-1617-9.

20. Ho J, Marks GB, Fox GJ. The impact of sputum quality on tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis. 2015 May; 19(5): 537 - 44. doi: 10.5588/ijtld.14.0798.

21. Davis JL, Cattamanchi A, Cuevas LE et al. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infectious Diseases, 2013, 13: 147 - 154.

22. IUATLD. Sputum examination for tuberculosis by direct microscopy in low income Countries: technical guide. 5. Paris: IUATLD; 2000.

23. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One. 2013; 8(2):e56074. doi: 10.1371/journal.pone.0056074.

24. Bonnett LJ, Davies GR Quality of outcome reporting in phase II studies in pulmonary tuberculosis. Trials. 2015 Nov 14; 16: 518. doi: 10.1186/s13063-015-1050-1.

25. Hepple P, Ford N, Mc Nerney R Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic review. Int J Tuberc Lung Dis. 2012 May; 16(5): 579 - 88. doi: 10.5588/ijtld.11.0617.

26. Migliori G.B., Zellweger J.P., Abubakar I. et al. European Union standards for tuberculosis care. Eur Respir J 2012; No 39 (4): 807 - 819. URL: http://dx.doi.org/10.1183/09031936.00203811.

27. Bauer M, Leavens A, Schwartzman K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Quality of Life Research 2013; 22(8): 2213 - 2235.

28. Bemer P., Palicova F., Rusch-Gerdes S. et al. Multicenter evaluation of fully automated BACTEC mycobacteria growth indicator tube 960 system for susceptibility testing of mycobacterium tuberculosis. J Clin Microbiol 2002; No 40 (1): 150 - 154.

29. Lin S. Y., Desmond E., Bonato D. et al. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of mycobacterium tuberculosis complex. J Clin Microbiol 2009; No 47 (11): 3630 - 3634.

30. Pfyffer G. E., Bonato D.A.. Ebrahimzadeh A. et al. Multicenter laboratory validation of susceptibility testing of mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; No 37 (10): 3179 - 3186.

31. Rusch-Gerdes S., Pfyffer G.E., Casal M. et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; No 44 (3): 688 - 692.

32. Siddiqi S. H., MGIT procedure manual. For BACTEC MGIT 960 TB system (Also applicable for Manual MGIT). Mycobacteria growth indicator tube (MGIT) culture and drug susceptibility demonstration projects. Foundation for innovative new diagnostics, 2006.

33. Denkinger CM, Schumacher SG, Boehme CC et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2014, doi: 10.1183/09031936.00007814.

34. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. European Respiratory Journal, 2008, 32: 1165 - 1174.

35. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(R) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Review of Molecular Diagnostics 2010. Oct; 10(7): 937 - 46.

36. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infectious Diseases 2005; 5: 62 - 70.

37. Boehme C.C., Nicol M.P., Nabeta P. et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; No 377 (9776): 1495 - 1505.

38. Lange C., Abubakar I., Alffenaar J.W. et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; No 44 (1): 23 - 63.

39. Rapid diagnostics of tuberculosis and its resistances. Nehren: Germany: Hain lifescience GmbH, 2015. http://www .hain-lifescience.de/uploadfiles/file/produkte/mikrobiologie/mykobakterien/tb_eng.pdf.

40. Hillery N., Groessl E.J., Trollip A. et al. The global consortium for drug-resistant tuberculosis diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 2014; No 15: 434 - 434.

41. Lienhardt C et al. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine, 2010, 16(3): 186 - 193.

42. Falzon D., Jaramillo E., et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; No 38 (3): 516 - 528.

43. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. 2006. International standards for tuberculosis care. Lancet Infect. Dis. 6: 710 - 725.

44. Wikman-Jorgensen P, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wikman-Jorgensen%20P%5BAuthor%5D&cauthor=true&cauthor_uid=25186265)Llenas-Garcia J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Llenas-Garc%C3%ADa%20J%5BAuthor%5D&cauthor=true&cauthor_uid=25186265)Hobbins M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Hobbins%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25186265)Ehmer J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ehmer%20J%5BAuthor%5D&cauthor=true&cauthor_uid=25186265)Abellana R, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Abellana%20R%5BAuthor%5D&cauthor-true&cauthor_uid=25186265)Goncalves AO, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Gon%C3%A7alves%20AO%5BAuthor%5D&cauthor=true&cauthor_uid=25186265) TM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=P%C3%A9rez-Porcina%20TM%5BAithor%5D&cauthor=true&cauthor_uid=25186265)Ascaso C. Microscopic observation drig sisceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis. E (https://www.ncbi.nlm.nih.gov/pi bmed/?term=Ascaso%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25186265)ur Respir J. 2014 Oct; 44(4): 973 - 84. doi: 10.1183/09031936.00079614. (https://www.ncbi.nlm.nih.gov/pubmed/25186265).

45. A systematic review of the sensitivity and specificity of symptom-and chest-radiography screening for active pulmonary tubercilosis in HIV-negative persons and persons with unknown HIV status. Geneva, World Health Organization, 2013 (https://www.ncbi.nlm.nih.gov/pubmed/25 186265).

46. Curtis J. Impact of x-ray screening programmes for active tuberculosis in homeless populations: asystematic review of original studies. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Curtis%20J%5BAuthor%5D&cauthor=true&cauthor_uid=25717042)J Public Health (Oxf). 2016 Mar; 38(1): 106 - 14. doi: 10.1093/pubmed/fdv014. (https://www.ncbi.nlm.nih.gov/pubmed/25717042).

47. Piccazzo R¹, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Piccazzo%20R%5BAuthor%5D&cauthor=true&cauthor_uid=24788998)Paparo F, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Paparo%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24788998)Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Garlaschi%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24788998)J Rheumatol Suppl. 2014 May; 91: 32 - 40. doi: 10.3899/jrheum.140100. (https://www.ncbi.nlm.nih.gov/pubmed/24788998).

48. Kienzl-Palma D, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Kienzl-Palma%20D%5BAuthor%5D&cauthor=true&cauthor_uid=27638823)Prosch H. Thoracic manifestation of tuberculosis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Prosch%20H%5BAuthor%5D&cauthor=true&cauthor_uid=27638823)Radiologe, 2016 Oct; 56(10): 866 - 873 (https://www.ncbi.nlm.nih.gov/pubmed/27638823)

49. Alkabab YM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Alkabab%20YM%5BAuthor%5D&cauthor=true&cauthor_uid=29379307)Enani MA, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Enani%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=29379307)Indarkiri NY, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Indarkiri%20NY%5BAuthor%5D&cauthor=true&cauthor_uid=29379307)Heysell SK. Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia. I (https://www.ncbi.nlm.nih.gov/pubmed/? term=Heysell%20SK%5BAuthor%5D&cauthor=true&cauthor_uid=29379307)nfect Drug Resist. 2018, 3; 11: 37 - 43. doi: 10.2147/IDR.S151844. (https://www.ncbi.nlm.nih.gov/pubmed/29379307).

50. Bauer CM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bauer%20CM%5BAuthor%5D&cauthor=true&cauthor_uid=27187878) A,(https://www.ncbi.nlm.nih.gov/pubmed/?term=Schm%C3%A4hl%20A%5BAuthor%5D&cauthor=true&cauthor_uid=27187878)Kreuter M. Imaging and Laboratory Diagnostics for Tuberculosis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Kreuter%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27187878)Klin Monbl Augenheilkd. 2016 May; 233(5): 587 - 93. doi: 10.1055/s-0042-104062. (https://www.ncbi.nlm.nih.gov/pubmed/27187878).

51. Zumla A, Raviglione M, Hafner R, et al. Tuberculosis. N Engl J Med 2013; 368: 745 - 55. (https://www.ncbi.nlm.nih.gov/pubmed/27187878).

52. Mondoni M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Mondoni%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28864395)Repossi A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Repossi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=28864395)Carlucci P, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Carlucci%20P%5BAuthor%5D&cauthor=true&cauthor_uid=28864395)Centanni S, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Centanni%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28864395)Sotgiu G. Bronchoscopic techniques in the management of patients with tuberculosis. I (https://www.ncbi.nlm.nih.gov/pubmed/?term=Sotgiu%20G%5BAuthor%5D&cauthor=true&cauthor_uid=28864395)nt J Infect Dis. 2017 Nov; 64: 27 - 37. doi: 10.1016/j.ijid.2017.08.008. Epub 2017 Aug 31. (https://www.ncbi.nlm.nih.gov/pubmed/28864395).

53. Парфенова Т.А. Опыт использования в противотуберкулезных учреждениях аллергена туберкулезного рекомбинантного для диагностики туберкулезной инфекции/Туберкулез и болезни легких, 2016, том 94, N 9, с. 49 - 52 (https://www.ncbi.nlm.nih.gov/pubmed/28864395).

54. Васильева И.А., Самойлова А.Г., Черноусова Л.Н., Багдасарян Т.Р., Черноусова Л.Н., Аксенова В.А., Баласанянц Г.С., Барышникова Л.А., Валиев Р.Ш., Казенный Б.Я., Казимирова Н.Е., Карпина Н.Л., Каюкова С.И., Клевно Н.И., Комиссарова О.Г., Ларионова Е.Е., Ловачева О.В., Марьяндышев А.О., Морозова Т.И., Перфильев А.В., Попов С.А., Пузанов В.А., Севастьянова Э.В., Скорняков С.Н., Стаханов В.А., Эргешов А.Э. Федеральные клинические рекомендации по диагностике и лечению туберкулеза органов дыхания. - Издание второе ООО "НЬЮ ТЕРРА, 2016. - 52 с (https://www.ncbi.nlm.nih.gov/pubmed/28864395).

55. Mota L, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Mota%20L%5BAuthor%5D&cauthor=true&cauthor_uid=27155187)Al-Efraij K, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Al-Efraij%20K%5BAuthor%5D&cauthor=true&cauthor_uid=27155187)Campbell JR, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Campbell%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=27155187)Cook VJ, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Cook%20VJ%5BAuthor%5D&cauthor=true&cauthor_uid=27155187)Marra F³, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Marra%20F%5BAuthor%5D&cauthor=true&cauthor_uid=27155187)Johnston J. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnston%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27155187)Int J Tuberc Lung Dis. 2016 Jun; 20(6): 819 - 26. doi: 10.5588/ijtld.15.0803. (https://www.ncbi.nlm.nih.gov/pubmed/27155187)

56. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bulletin of the World Health Organization, 2004, 82: 935 - 939. (https://www.ncbi.nlm.nih.gov/pubmed/27155187).

57. Karumbi J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Karumbi%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26022367)Garner P. Directly observed therapy for treating tuberculosis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Garner%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26022367)Cochrane Database Syst Rev. 2015 May 29; (5):CD003343. doi: 10.1002/14651858.CD003343.pub4. (https://www.ncbi.nlm.nih.gov/pubmed/26022367).

58. Yin J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yin%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26930287)Yuan J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yuan%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26930287)Hu Y, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Hu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=26930287)Wei X Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wei%20X%5BAuthor%5D&cauthor=true&cauthor_uid=26930287)LoS One. 2016 Mar 1; 11(3): e0150511. doi: 10.1371/journal.pone.0150511 (https://www.ncbi.nlm.nih.gov/pubmed/26930287).

59. Wang XM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20XM%5BAuthor%5D&cauthor=true&cauthor_uid=16737577)Liu JJ, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=16737577)Wang J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=16737577)Wu T, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20T%5BAuthor%5D&cauthor=true&cauthor_uid=16737577)Zhan SY. Systematic review of directly observed therapy on tuberculosis control in China. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhan%20SY%5BAuthor%5D&cauthor=true&cauthor_uid=16737577)Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Jan; 27(1): 63 - 7. e1000150. (https://www.ncbi.nlm.nih.gov/pubmed/16737577).

60. Johnston JC, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Johnston%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=28203783)Campbell JR, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Campbell%20JR%5BAuthor%5D&cauthor=true&cauthor_uid=28203783)Menzies D. Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Menzies%20D%5BAuthor%5D&cauthor=true&cauthor_uid=28203783)lin Infect Dis. 2017 May 1; 64(9): 1211 - 1220. doi: 10.1093/cid/cix121 (https://www.ncbi.nlm.nih.gov/pubmed/28203783).

61. Chunlan Zheng, Xiufen Hu, Li Zhao, Minhui Hu, Feng Gao Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?//Dove Medical Press Limited, 2017; 11: 2957 - 2968.

62. Васильева И.А., Багдасарян Т.Р., Баласанянц Г.С., Богородская Е.М., Борисов С.Е., Валиев Р.Ш., Казенный Б.Я., Казимирова Н.Е., Краснов В.А., Ловачева О.В., Малиев Б.М., Марьяндышев А.О., Морозова Т.И., Самойлова А.Г., Севастьянова Э.В., Скорняков С.Н., Смердин С.В., Стаханов В.А., Черноусова Л.Н., Эргешов А.Э. Федеральные клинические рекомендации по диагностике и лечению туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью возбудителя. - Издание третье РОФ - Москва, 2015. - 68 с.

63. Bastos ML, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bastos%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Hussain H, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Hussain%20H%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Weyer K, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Weyer%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Garcia-Garcia L, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Garcia-Garcia%20L%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Leimane V, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Leimane%20V%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Leung CC, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Leung%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Narita M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Narita%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25097082), (https://www.ncbi.nlm.nih.gov/pubmed/?term=Pen%C3%A3%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Ponce-de-Leon A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ponce-de-Leon%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Seung KJ, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Seung%20KJ%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Shean K, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Shean%20K%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Sifuentes-Osornio J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Sifuentes-Osornio%20J%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Van der Walt M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20der%20Walt%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Van der Werf TS, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20der%20Werf%20TS%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Yew WW, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yew%20WW%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Menzies D; (https://www.ncbi.nlm.nih.gov/pubmed/?term=Menzies%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25097082)Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Collaborative%20Group%20for%20Meta-analysis%20of%20Individual%20Patient%20Data%20in%20MDR-TB%5BCorporate%20Author%5D)Clin Infect Dis. 2014 Nov 15; 59(10): 1364 - 74. doi: 10.1093/cid/ciu619. (https://www.ncbi.nlm.nih.gov/pubmed/25097082).

64. Fryatt RJ. Review of published cost effectiveness studies on tuberculosis treatment programmes. International Journal of Tuberculosis and Lung Disease, 1997, 1: 101 - 109. (https://www.ncbi.nlm.nih.gov/pubmed/25097082).

65. Gegia M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Gegia%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27865891)Winters N, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Winters%20N%5BAuthor%5D&cauthor=true&cauthor_uid=27865891)Benedetti A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Benedetti%20A%5BAuthor%5D&cauthor=true&cauthor_uid=27865891)van Soolingen D, (https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Soolingen%20D%5BAuthor%5D&cauthor=true&cauthor_uid=27865891)Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Menzies%20D%5BAuthor%5D&cauthor=true&cauthor_uid=27865891)Lancet Infect Dis. 2017 Feb; 17(2): 223 - 234. doi: 10.1016/S1473-3099(16)30407-8. (https://www.ncbi.nlm.nih.gov/pubmed/27865891).

66. Lee H., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20H%5BAuthor%5D&cauthor=true&cauthor_uid=26525801) Jeong BH., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeong%20BH%5BAuthor%5D&cauthor=true&cauthor_uid=26525801) Park HY., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Park%20HY%5BAuthor%5D&cauthor=true&cauthor_uid=26525801) Jeon K., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Jeon%20K%5BAuthor%5D&cauthor=true&cauthor_uid=26525801) Huh H J., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Huh%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=26525801) Lee NY., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20NY%5BAuthor%5D&cauthor=true&cauthor_uid=26525801) Koh WJ. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis (https://www.ncbi.nlm.nih.gov/pubmed/?term=Koh%20WJ%5BAuthor%5D&cauthor=true&cauthor_uid=26525801)Antimicrob Agents Chemother. 2016 Jan; 60(1): 471 - 477. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704191/).

67. Colebunders R, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Colebunders%20R%5BAuthor%5D&cauthor=true&cauthor_uid=10694086)Bastian I A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bastian%20I%5BAuthor%5D&cauthor=true&cauthor_uid=10694086)Int J Tuberc Lung Dis. 2000 Feb; 4(2): 97 - 107. (https://www.ncbi.nlm.nih.gov/pubmed/10694086).

68. Seifert M., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Seifert%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25799046) Catanzaro D., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Catanzaro%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25799046) Catanzaro A., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Catanzaro%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25799046)Rodwell T. C. Genetic mutations associated with isoniazid resistance in mycobacterium tuberculosis: A systematic review PLoS One 2015; No 10 (3): e0119628. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Rodwell%20TC%5BAuthor%5D&cauthor=true&cauthor_uid=25799046).

69. Ahuja S.D., Ashkin D., Avendano M. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; No 9 (8): e1001300. URL: (https://www.ncbi.nlm.nih.gov/pubmed/?term=Rodwell%20TC%5BAuthor%5D&cauthor=true&cauthor_uid=25799046) http://dx.doi.org/10.1371/journal.pmed.1001300 (http://dx.doi.org/10.1371/journal.pmed.1001300).

70. (http://dx.doi.org/10.1371/journal.pmed.1001300)Meyssonnier V., van Bu Th. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bui%20TV%5BAuthor%5D&cauthor=true&cauthor_uid=24410906), Veziris (https://www.ncbi.nlm.nih.gov/pubmed/?term=Veziris%20N%5BAuthor%5D&cauthor=trie&cauthor_uid=24410906) N. et al. Rifampicin mono-resistant tuberculosis in France: a 2005 - 2010 retrospective cohort analysis. DVC Infect Dis 2014; No 14: 18 - 18.

71. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis, 2009; 9: 153 - 61.

72. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009 Sep 9; 4(9):e6914..

73. Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis: MSc thesis. Monreal, 2010.

74. Winters N., Butler-Laporte G., Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015; No 46 (5): 1461 - 1470.

75. Lew W., Pai M., Oxlade O. et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; No 149 (2): 123 - 134.

76. Shandil R.K., Jayaram R., Kair P., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; No 51 (2): 576 - 582.

77. Falzon D., Gandhi N., Migliori G.B. et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; No 42 (1): 156 - 168.

78. Ziganshina L. E., Squire S. B. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst. Rev. - 2008.

79. Синицын, М.В. в хирургическом лечении больных туберкулезом легких/М.В. Синицын, И.В. Богадельникова//Проблемы туберкулеза. - 2007. - N 5. С. - 17 - 20.

80. Фещенко Ю.И., Ищук С.Г., Матвиенко Ю.А. Терапевтические возможности инновационного модулятора в пульмонологии и фтизиатрии. пульмонологiчний журнал. 2012, N 3, стр. 50 - 54.

81. Zignol M., (https://www.ncbi.nlm.nih.gov/pi bmed/?term=Zignol%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27397590)Dean A.S., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Dean%20AS%5BAuthor%5D&cauthor=true&cauthor_uid=27397590)Alikhanova N. et al. Population-based resistance of mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 2016; No 16 (10): 1185 - 1192. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Alikhanova%20N%5BAuthor%5D&cauthor=true&cauthor_uid=27397590).

82. Naidoo A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Naidoo%20A%5BAuthor%5D&cauthor=true&cauthor_uid=28741299)Naidoo K, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Naidoo%20K%5BAuthor%5D&cauthor=true&caithor_uid=28741299)McIlleron H, (https://www.ncbi.nlm.nih.gov/pubmed/?term=McIlleron%20H%5BAuthor%5D&cauthor=true&cauthor_iid=28741299)Essack S, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Essack%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28741299)Padayatchi N.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis/J Clin Pharmacol. 2017 Nov; 57(11): 1369 - 1386. doi: 10.1002/jcph.968 (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

83. Miotto P., Cabibbe A.M., Feierriegel S. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio 2014; No 5 (5): 01819 - 01820. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

84. Wells W.A., Boehme C.C., Cobelens F.G.J. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013; No 13 (5): 449 - 458. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

85. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377(9760): 147 - 52 (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

86. Pontali E, Sotgiu G, D"Ambrosio L, et al. Bedaqiiline and MDR-TB: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394 - 402. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

87. Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators. Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versis Acqiired Second-Line Drug Resistance Clin Infect Dis. 2016 Feb 15; 62(4): 418 - 30. doi: 10.1093/cid/civ910. Epib 2015 Oct 27 (https://www.ncbi.nlm.nih.gov/pubmed/? term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

88. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis, interim policy guidance. Geneva: WHO, 2013. URL: http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

89. Sotgiu G., Centis R., D'Ambrosio L., Alffenaar J.W.C., Anger H.A., Caminero J.A., Castiglia P., de Lorenzo S., Ferrara G., Koh W.J., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur. Respir. J. 2012; 40: 1430 - 1442. doi: 10.1183/09031936.00022912. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

90. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; No 16 (4): 447 - 454. (https://www.ncbi.nlm.nih.gov/pubmed/? term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

91. Jacobson K.R., Tierney D.B., Jeon C.Y. et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; No 51 (1): 6 - 14. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

92. De Lorenzo S. et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB//European Respiratory Journal. - 2013. - Vol. 41, N 6. - Р. 1386 - 1392. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

93. Villar M., Sotgiu G., D'Ambrosio L., Raymundo E., Fernandes L., Barbedo J., Diogo N., Lange C., Centis R., Migliori G.B. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J. 2011; 38: 730 - 733. doi: 10.1183/09031936.00195210. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

94. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, PageShipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375(9728): 1798 - 807. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299).

95. G. Sotgiu, L. D'Ambrosio, R. Centis, S. Tiberi, S. Esposito, S. Dore. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review/Int J Mol Sci, 17, (2016), (https://www.ncbi.nlm.nih.gov/pubmed/?term=Padayatchi%20N%5BAuthor%5D&cauthor=true&cauthor_uid=28741299)http://dx.doi.org/10.3390/ijms17111904 (http://dx.doi.org/10.3390/ijms17111904).

96. World Health Organization. Model list of essential medicines 19th list. Geneva: WHO, 2015. URL: (http://dx.doi.org/10.3390/ijms17111904)http://www.who.int/selection_medicines/committees/expert/20/EML2015_FINAL_amende (http://www.who.int/selection_medicines/committees/expert/20/EML2015_FINAL_amended_AUG2015.pdf).

97. Van Rijn S.P., van Altena R., Akkerman O.W., van Soolingen D., van der Laan T., de Lange W.C.M., Kosterink J.G.W., van der Werf T.S., Alffenaar J.W.C. Pharmacokinetics evaluation of ertapenem in patients with treatment of multidrug-resistant tuberculosis. Eur. Respir. J. 2016 in press. (http://www.who.int/selection_medicines/committees/expert/20/EML2015_FINAL_amended_AUG2015.pdf).

98. Payen M.C., de Wit S., Martin C., Sergysels R., Muylle I., van Laethem Y., Clumeck N. Clinical use of meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012; 16: 558 - 560. doi: 10.5588/ijtld.11.0414. (http://www.who.int/selection_medicines/committees/expert/20/EML2015_FINAL_amended_AUG2015.pdf).

99. Tiberi S.G., Sotgiu, L. D'Ambrosio, R. Centis, M. Abdo Arbex, E. Alarcon Arrascue. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB/Eur Respir J, (2016), (http://www.who.int/selection_medicines/committees/expert/20/EML2015_FINAL_amended_AUG2015.pdf)http://dx.doi.org/10.118 2016 (http://dx.doi.org/10.1183/13993003.00214-2016).

100. Tiberi, S.G. Sotgiu, L. D'Ambrosio, R. Centis, M.A. Arbex, E. Alarcon Arrascue. Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug (http://dx.doi.org/10.1183/13993003.00214-2016).

101. World Health Organization. Treatment guidelines for drug-resistant tuberculosis. Geneva: WHO, 2016. (http://dx.doi.org/10.1183/13993003.00214-2016).

102. WHO Regional Office for Europe The role of surgery in the treatment of pulmonary TB and multidrug- and extensively drug-resistant TB, 2014 (http://dx.doi.org/10.1183/13993003.00214-2016).

103. Marrone MT, Venkataramanan V, Goodman M, Hill AC, Jereb JA, Mase SR. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013; 17(1): 6 - 16 (http://dx.doi.org/10.1183/13993003.00214-2016).

104. Васильева И.А., Сигаев А.Т., Чуканов В.И. Искусственный пневмоперитонеум в комплексном лечении больных туберкулезом легких, выделяющих лекарственно-устойчивые микобактерии туберкулеза//Проблемы туберкулеза и болезней легких. - 2006. - N 8. - С. 23 - 26. (http://dx.doi.org/10.1183/13993003.00214-2016).

105. Кильдюшева Е.И., Скорняков С.Н., Медвинский И.Д., Мотус И.Я., Залетаева Г.Е., Савельев А.В. Пневмоперитонеум в комплексном лечении распространенных форм деструктивного туберкулеза легких//Уральский медицинский журнал. - 2013. - N 2. - С. 69 - 75. (http://dx.doi.org/10.1183/13993003.00214-2016).

106. Левин А.В., Цеймах Е.А., Зимонин П.Е. Применение клапанной бронхоблокации при осложненном туберкулезе легких. - Барнаул, 2008. - 29 с. (http://dx.doi.org/10.1183/13993003.00214-2016).

107. Ловачева О.В., Сивокозов И.В., Эргешов А.Э., Васильева И.А., Багдасарян Т.Р. Использование клапанного бронхоблокатора в лечении больных с деструктивным туберкулезом легких//Проблемы туберкулеза и болезней легких. - 2008. - N 10. - С. 58 - 61. (http://dx.doi.org/10.1183/13993003.00214-2016).

108. Ловачева О.В., Шумская И.Ю., Туровцева Ю.В., Васильева И.А., Эргешов А.Э. Эндобронхиальный клапан в лечении деструктивного лекарственно-устойчивого туберкулеза//Туберкулез и болезни легких. - 2011. - N 5. - С. 28 - 29. (http://dx.doi.org/10.1183/13993003.00214-2016).

109. Ерохин В.В. О некоторых механизмах патогенеза туберкулеза/Проблемы туберкулеза. - 2009. - N 11. - С. 3 - 8. (http://dx.doi.org/10.1183/13993003.00214-2016).

110. Ерохин В.В., Ловачева О.В., Лепеха Л.Н., Васильева И.А., Багдасарян Т.Р., Розенберг О.А. Комплексное лечение деструктивного туберкулеза легких с использованием препарата природного сурфактанта "сурфактант-БЛ". Методические рекомендации. - М., 2010. - 22 с. (http://dx.doi.org/10.1183/13993003.00214-2016).

111. (http://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%A9ndez-Samperio%20P%5bAuthor%5d&cauthor=true&cauthor_uid=24815775)Samperio (http://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%A9ndez-Samperio%20P%5bAuthor%5d&cauthor=true&cauthor_uid=24815775) P. Immunotherapy for human TB: evidence for adjuvant activities of some host defense peptides against TB./Immunotherapy, 2014; 6(4): 363 - 5. doi: 10.2217/imt.14.8. (http://www.ncbi.nlm.nih.gov/pubmed/?term=M%C3%A9ndez-Samperio%20P%5bAuthor%5d&cauthor=true&cauthor_uid=24815775).

112. Wang M, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20M%5bAuthor%5d&cauthor=true&cauthor_uid=25861717)Guan X, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Guan%20X%5bAuthor%5d&cauthor=true&cauthor_uid=25861717)Chi Y, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Chi%20Y%5bAuthor%5d&cauthor=true&cauthor_uid=25861717)Robinson N, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Robinson%20N%5bAuthor%5d&cauthor=true&cauthor_uid=25861717)Liu JP. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials./Tuberculosis (Edinb.) 2015 Mar 18. pii: S1472-9792(14)20598-1. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

113. Абрамова Н.Н., Симбирцев А.С., Долгушин И.И. Влияние Бестима и Беталейкина на иммунный статус больных с вторичными иммунодефицитными состояниями при вакцинации против вирусного гепатита B//Цитокины и воспаление. - 2004. - Т. 3. - N 4. - С. 29 - 35 (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

114. Зурочка В.А., Долгушин И.И., Симбирцев А.С. Влияние иммуномодулятора Бестим in vitro на спонтанную и индуцированную продукцию цитокинов , , IL-4, IL-8, IL-10 иммунокомпетентными клетками крови здоровых лиц//Цитокины и воспаление. - 2007. - Т. 6. - N 1. - С. 31 - 35 (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

115. Simbirtsev A., Kolobov A., Zabolotnych N., Pigareva N., Konusova V., Kotov A., Variouchina E., Bokovanov V., Vinogradova T., Vasilieva S., Tuthill C. Biological Activity of Peptide SCV-07 Against Murine Tuberculosis//Russ J Immunol. - 2003. - V.8. - N 1. - P. 11 - 22 (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

116. Арчакова Л.И. Комплексная терапия больных инфильтративным туберкулезом легких с применением рекомбинантных цитокинов автореферат дисс. канд. мед. наук/СПб. - 2001. - 24 с. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

117. Басек Т.С. Предоперационная иммунокоррекция рекомбинантным IL-2 (Ронколейкин) больных прогрессирующим фиброзно-кавернозным туберкулезом автореферат дисс. канд. мед. наук/СПб. - 2000. - 20 с. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

118. Васильева Г.Ю. Повышение эффективности комплексного лечения деструктивного туберкулеза легких с применением иммуномодулятора Бестим: автореферат дисс. канд. мед. наук/СПб. - 2004. - 22 с. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

119. Ковалева Р.Г. Амиксин в комплексной терапии больных инфильтративным туберкулезом: автореферат дисс. канд. мед. наук/СПб. - 2006. - 22 с. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

120. Перельман М.И., Хомяков Ю.Н., Киселев В.И. [и др.]. Молекулярная медицина и лечение туберкулеза/Проблемы туберкулеза. - 2001. - N 3. - С. 69 - 72. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

121. Easton D.M., Nijnik A., Mayer M.L., Hancock R. E.W. Potential of immunomodulatory host defense peptides as novel anti-infectives/Trends in Biotechnology. - 2009. - V. 27, N.10. - P. 582 - 590. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

122. Filomeni G., Rotilio G., Ciriolo M.R. 2002. Cell signalling and the glutathione redox system./Biochem. Pharmacol. 64: 1057 - 1064. (http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20JP%5bAuthor%5d&cauthor=true&cauthor_uid=25861717).

123. Sarin P, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Sarin%20P%5BAuthor%5D&cauthor=true&cauthor_uid=27046721)Duffy J, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Duffy%20J%5BAuthor%5D&cauthor=true&cauthor_uid=27046721)Mughal Z, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Mughal%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=27046721)Hedayat E, (http://www.ncbi.nlm.nih.gov/pubmed/?term=Hedayat%20E%5BAuthor%5D&cauthor=true&cauthor_uid=27046721)Manaseki-Holland S. Vitamin D and tuberculosis: review and association in three rural provinces of Afghanistan//Int J Tuberc Lung Dis. 2016; 20(3): 383 - 8 (http://www.ncbi.nlm.nih.gov/pubmed/?term=Manaseki-Holland%20S%5BAuthor%5D&cauthor=true&cauthor_uid=27046721).

124. Zittermann A, Pilz S, Hoffmann H, Vitamin D and airway infections: a European perspective.//Eur J Med Res. 2016; 24; 21:14.

125. Pareek M, Innes J, Sridhar S, Grass L, Connell D, Woltmann G, Wiselka M, Martineau AR, Kon OM, Dedicoat M, Lalvani A. Vitamin D deficiency and TB disease phenotype.//Thorax. 2015; 70(12): 1171 - 80.

126. Ralph AP, Waramori G, Pontororing GJ, et al. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS One. 2013; 8:e70032.

127. Cegielski P, Vernon A. Tuberculosis and vitamin D: what"s the rest of the story?//Lancet Infect Dis. 2015; 15(5): 489 - 90.

128. WHO. Treatment of tuberculosis: guidelines 2010. 4th ed. Geneva: WHO/HTM/TB/2009. 420; 2010.

129. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva: WHO, 2011. URL: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf (http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf).

130. Г.С. Баласанянц. Концепция развития фтизиатрической санаторной помощи больным туберкулезом в Российской Федерации Медицинский альянс научно-практический журнал. - СПб, 2013. - N 4. - стр. 79 - 83. (http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf).

131. Инструкция по химиопрофилактике туберкулеза у взрослых больных ВИЧ-инфекцией, 2016, 8 с. (http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf).

132. Синицы М.В., Аюшева Л.Б., Колпакова Л.В. Совершенствование химиопрофилактики у больных ВИЧ-инфекцией. Медицинский вестник юга России, 2016, N 4, стр. 28 - 32 (http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf).

133. Datiko DG, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Datiko%20DG%5BAuthor%5D&cauthor=true&cauthor_uid=28826449)Yassin MA, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yassin%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=28826449)Theobald SJ, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Theobald%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=28826449)Cuevas LE. A community-based isoniazid preventive therapy for the prevention of childhood tuberculosis in Ethiopia. I (https://www.ncbi.nlm.nih.gov/pubmed/?term=Cuevas%20LE%5BAuthor%5D&cauthor=true&cauthor_uid=28826449)nt J Tuberc Lung Dis. 2017 Sep 1; 21(9): 1002 - 1007. doi: 10.5588/ijtld.16.0471. (https://www.ncbi.nlm.nih.gov/pubmed/28826449).

134. Okwara FN, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Okwara%20FN%5BAuthor%5D&cauthor=true&cauthor_uid=28915796)Oyore JP, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Oyore%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=28915796)Were FN, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Were%20FN%5BAuthor%5D&cauthor=true&cauthor_uid=28915796)Gwer S. Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Gwer%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28915796)BMC Infect Dis. 2017 Sep 16; 17(1): 623. doi: 10.1186/s12879-017-2719-8. (https://www.ncbi.nlm.nih.gov/pubmed/28915796).

135. Руководство по ведению пациентов с латентной туберкулезной инфекцией, 2015, 40 с.